[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100406980":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":64,"collaborators":66,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":10,"studyType":89,"phases":10,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Universitaire Ziekenhuizen KU Leuven","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Transplanted patients",null,"All patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven",[13],"Diagnostic Test: SARS-CoV-2 IgG",{"label":15,"type":10,"description":16,"interventionNames":17},"Transplanted patients with past SARS-CoV-2 infection","Transplanted patients with past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Transplanted patients without past SARS-CoV-2 infection","100 transplanted patients without past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity and as control for the transplanted patients with WITH past SARS-CoV-2 infection",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","SARS-CoV-2 IgG","Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies",[9,15,19],[29],{"name":30,"affiliation":31,"role":32},"Jef Verbeek, MD, PhD","UZ Leuven","PRINCIPAL_INVESTIGATOR",[34,38],{"name":30,"role":35,"phone":36,"phoneExt":10,"email":37},"CONTACT","+ 32 16 34 42 25","jef.verbeek@uzleuven.be",{"name":39,"role":35,"phone":40,"phoneExt":10,"email":41},"Natalie Van den Ende","+32 16 340749","natalie.vandenende@uzleuven.be",[43],{"facility":31,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Leuven","Vlaams Brabant","3000","Belgium","BE",{"type":51,"coordinates":52},"Point",[53,54],4.70093,50.87959,{"lat":54,"lon":53},[57,60,63],{"name":58,"role":35,"phone":59,"phoneExt":10,"email":37},"Jef Verbeek, MD","+32 16 345845",{"name":61,"role":35,"phone":62,"phoneExt":10,"email":41},"Natalie Vandenende","+32 16 34 07 49",{"name":58,"role":32,"phone":10,"phoneExt":10,"email":10},{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[67,69,71,73],{"name":68,"class":6},"KU Leuven",{"name":70,"class":6},"Hasselt University",{"name":72,"class":6},"Ziekenhuis Oost-Limburg",{"name":74,"class":6},"Jessa Hospital","100406980","prevalence-and-outcome-of-sars-cov-2-infection--covid-19-in-transplant-recipients-the-covitra-study-100406980",false,"NCT04579471","Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study","Prevalence and Outcome of SARS-CoV-2 Infection in Solid Organ and Hematopoietic Cell Transplant Recipients: The COVITRA Study","COVITRA","Inclusion Criteria:\n\n* all patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven and who give informed consent\n\nExclusion Criteria:\n\n* age under 18 years","ALL","18 Years","90 Years",{"count":87,"type":88},2000,"ESTIMATED","OBSERVATIONAL","This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.",[92,93,94],"Covid19","SARS-CoV Infection","Transplantation Infection",[96,93,97],"covid19","transplantation","2024-07-02",{"date":100,"type":101},"2024-07-03","ACTUAL",{"date":103,"type":101},"2020-07-01",{"date":105,"type":88},"2025-12-31",{"name":5,"class":6},1]